We are a holding company incorporated in Singapore (that) oversees our operations in Malaysia. The company was formerly known as CytoMed Therapeutics Pte. Ltd. We conduct our business activities primarily through our direct wholly owned subsidiary in Malaysia, CytoMed Malaysia, but may be commencing more research and clinical trial activities in Singapore through CytoMed moving forward. […]

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). Tregs consist of CD4+CD25high hFOXP3+ cells, which are a sub-population of T-lymphocytes, a type of white blood cell that suppresses inflammatory responses. We are initially focused on developing our Treg-based therapies for neurodegenerative, autoimmune […]

We are a global lifestyle and fashion brand with a license agreement with soccer legend Lionel Messi, also known as Leo Messi. (Incorporated in Delaware) The Messi Brand design team is led by MGO co-founder and Chief Design Officer Virginia “Ginny” Hilfiger, who works in close collaboration with Leo Messi to craft the fundamental design […]

We are a forward-thinking (and) growth-driven energy company focused on creating value for our stockholders through the organic development of our properties as well as accretive acquisitions. (Incorporated in Delaware) Our core business is to produce natural gas from our owned and operated upstream businesses, which we expect to achieve net zero Scope 1 and […]

(Note: Lucy Scientific Discovery Inc. downsized its IPO at pricing on Feb. 8, 2023, to 1.875 million shares – down from 2.0 million shares in the prospectus – and priced the IPO at $4.00, as planned, to raise $7.5 million. (Source: Company announcement on Feb. 8, 2023, after the U.S. stock market’s close.)  Background: Lucy […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTC Market. On Nov. 15, 2022, the last reported sale price for our common stock was $13.125 per share, reflecting an expected common stock reverse split at a ratio of 1-for-750 to be effected prior to the closing of the Underwritten Offering.)  Atlas […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTCQB Venture Market.) Our mission is to provide novel diagnostic tools that optimize outcomes and quality of life for all patients along the continuum of oncology care, from cancer screening through treatment and monitoring.  We have one wholly owned subsidiary: StemPrintER Sciences […]

(Note: TXO Energy Partners, L.P., priced its IPO on Jan. 26, 2023, at $20.00 – the mid-point of its $19.00-to-$21.00 range – on 5.0 million common units to raise $100 million. The IPO was priced in sync with the terms in its prospectus. The company was formerly knowns as Morningstar Partners L.P. TXO Energy Partners […]

(Note: SYLA Technologies Co. Ltd. priced its IPO on March 30, 2023, in sync with the terms in its prospectus: 1.88 million American Depositary Shares (1,875,000 ADS) at $8.00 to raise $15.0 millon. SYLA Technologies Co. Ltd. filed an F-1/A dated Jan. 12, 2023, in which it disclosed that its IPO would be a NASDAQ […]

(Note: GP-Act III Acquisition Corp., a Cayman Islands-incorporated blank check company, withdrew its SPAC IPO plans in an SEC filing dated Nov. 16, 2022. GP-Act III Acquisition’s S-1 was filed in March 2021.) We intend to focus our search on high potential consumer-facing businesses based in the United States.